Starling Oncology vs Teladoc Health
STLN and TDOC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How STLN and TDOC compare
Teladoc Health is the larger company, worth 2.3 times as much as Starling Oncology ($1.5B against $666M).
Starling Oncology grew revenue faster over the last twelve months (38.4% versus −2.4% for Teladoc Health).
Starling Oncology keeps more of each dollar of sales as profit, with a net margin of −6.2% compared with −6.3% at Teladoc Health.
Starling Oncology scores higher on the StockData Score (6 against 4 for Teladoc Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | STLN | TDOC |
|---|---|---|
| Size and price | ||
| Market cap | $666M | $1.5B |
| Share price | $6.53 | $8.51 |
| Change, 1 year | 38.9% | 3.4% |
| Change, 5 years | −34.6% | −94.2% |
| Beta (5Y) | 1.60 | 2.06 |
| Employees | 641 | 5,600 |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 1 | 3 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.1× | 0.6× (better) |
| P/B | – | 1.2× |
| P/FCF | – | 5.9× |
| FCF yield | −0.49% | 16.9% (better) |
| Fair value | – | $13.77 |
| Margin of safety | – | 38.2% |
| Growth | ||
| Revenue growth (TTM) | 38.4% (better) | −2.4% |
| Revenue growth, 5Y average | 21.8% (better) | 18.3% |
| Profitability | ||
| Gross margin | – | 68.6% |
| Operating margin | −4.4% (better) | −6.6% |
| Net margin | −6.2% (better) | −6.3% |
| FCF margin | −0.56% | 10.6% (better) |
| Return on equity | – | −11.5% |
| Return on invested capital | −83.1% | −23.2% (better) |
| Financial health | ||
| Interest coverage | −3.4× (better) | −8.0× |
| Current ratio | 1.36 (better) | 0.87 |
| Altman Z-score | 2.78 (better) | −7.11 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 43.4% | 83.9% |
| Held by insiders | 56.6% | 0.72% |
| Insider net buying, 12 months | −$122K (better) | −$2.3M |
| Short interest, % of float | – | 16.7% |
Go deeper
- STLN stock overview
- STLN income statement
- STLN valuation and score
- TDOC stock overview
- TDOC income statement
- TDOC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.